Dedicated to the study and treatment of people with schizophrenia since 1989.
ABOUT US
Since 1989, the Treatment Research Program (TRP) has been committed to advancing the understanding and treatment of schizophrenia. Our mission is to improve the lives of individuals living with schizophrenia by conducting innovative research, including clinical trials of new medications and strategies that support recovery.
​
Challenges in Schizophrenia Treatment
While significant progress has been made in understanding schizophrenia over the past decade, the development of new treatments has lagged. Translating research breakthroughs into effective medications has proven difficult, and many patients still face barriers to achieving optimal outcomes due to the lack of personalized treatment approaches.
Current treatments often do not account for the complex and diverse nature of schizophrenia. Most therapies are developed based on broad diagnostic criteria, which doesn't reflect the individual differences in how the condition manifests. This one-size-fits-all approach leaves many patients without the tailored care they need.
​
The Need for Personalized Care
Schizophrenia affects people in different ways, and so do its treatments. As a result, successful treatment can be a struggle. At the TRP, we are driven by a commitment to personalized medicine—developing treatments that address the unique needs of each patient, rather than relying on generalized approaches.
Key Components of the Treatment Research Program
A cornerstone of the TRP is the partnership established between the Maryland Psychiatric Research Center and Spring Grove Hospital Center. This partnership unites leading clinical and research professionals, fostering collaboration to deliver cutting-edge, innovative care.
Additionally, the TRP operates a Brief Stay Unit (BSU)—a 3-bed, research-focused short-stay facility dedicated to early-phase clinical studies and challenge studies. The unit is fully equipped with emergency care resources and staffed by trained research professionals, ensuring the highest standards of safety and care.
The TRP also offers specialized consultation and referral services, including national initiatives like the clozapine program, which aims to overcome treatment barriers. Through partnerships with community health centers, clinics, and private practices, we extend research opportunities to as many individuals with schizophrenia as possible, even those living in the community.
Referral Process and Participation Opportunities
The TRP is actively enrolling new participants for a variety of research studies, including behavioral studies, medication trials, and more. We welcome individuals with and without a history of mental illness to participate. Our studies offer an opportunity to contribute to the advancement of schizophrenia research while receiving cutting-edge care.
OUR RESEARCH
Led by Dr. Deanna Kelly, the Treatment Research Program (TRP) at the Maryland Psychiatric Research Center is dedicated to advancing personalized treatment strategies for individuals with schizophrenia. Our team’s research aims to tailor therapies based on the unique biological and clinical characteristics of each patient, focusing particularly on underexplored areas in schizophrenia care.
​
Women and Schizophrenia
Dr. Kelly’s team is one of the few research groups that specifically investigates the biological differences and treatment side effects experienced by women with schizophrenia. By recognizing and addressing these gender-specific challenges, the team is working to create more effective, personalized treatment options for women with the condition.
Clozapine and Genetic Predispositions
Another major focus of TRP’s research is improving the use of clozapine, a medication for treatment-resistant schizophrenia. The team is leading a large multinational clinical trial aimed at optimizing clozapine treatment, particularly in patients of African descent. This population may have a genetic predisposition to certain side effects, and the study is designed to ensure safe and effective use of clozapine for these individuals, addressing the specific genetic factors that may influence their response to the drug.
​
Innovations in Technology and Biomarkers
The TRP is also at the forefront of integrating new technologies into schizophrenia research. This includes innovative methods for analyzing language and social media to track symptoms, advanced techniques for detecting medication levels in the body, and the development of novel biomarkers to enhance diagnosis and treatment precision.
Dietary Intervention
Dr. Kelly’s team has extensive experience researching the connection between diet and schizophrenia, particularly in relation to inflammation and immune responses. In collaboration with Johns Hopkins University and Harvard, the group has explored dietary factors like gluten sensitivity, discovering that some individuals with schizophrenia exhibit elevated antibodies against gliadin, a protein found in wheat and other grains. Our research has contributed to a deeper understanding of how dietary changes, such as adopting a gluten-free diet, may benefit certain patients by reducing inflammation and improving psychiatric outcomes.
Building on this expertise, our team has also studied the medical ketogenic diet and its potential to support brain health and symptom management in schizophrenia. In addition, we are currently running a study on prebiotics, actively exploring how these supplements can improve gut health and further enhance mental well-being through better immune regulation.
OUR TEAM
Director and Chief of Treatment Research Program
410 402 6861
AnnMarie Kearns, MS
Director of Research Operations and Compliance
410 402 6854
Professor of Psychiatry
410-402-6806
(443) 571-0086
(410) 402-6412
Clinical Research Assistant
Emma DuMez
Donna Dadkhoo
Clinical Research Assistant
Treatment Research Unit
Gopal Vyas, DO
Psychiatrist and Unit Director
Clinical Assistant Professor
(410) 402-6865
Heather A. Adams, PsyD
Clinical Psychologist
Clinical Assistant Professor
(410) 402-6818
PUBLISHED WORK
Listed below are highlighted articles. Click here to view more of Dr. Deanna Kelly's published work.
July 2019
Kelly DL, Demyanovich HK, Rodriguez KM, Ciháková D, Talor MV, McMahon RP, Richardson CM, Vyas G, Adams HA, August SM, Fasano A, Cascella NG, Feldman SM, Liu F, Sayer MA, Powell MM, Wehring HJ, Buchanan RW, Gold JM, Carpenter WT, Eaton WW. Randomized controlled trial of a gluten-free diet in patients with schizophrenia positive for antigliadin antibodies (AGA IgG): a pilot feasibility study. J Psychiatry Neurosci. 2019 Jul 1;44(4):269-276. doi: 10.1503/jpn.180174. PMID: 30938127; PMCID: PMC6606425.
Approximately one-third of people with schizophrenia have elevated levels of anti-gliadin antibodies of the immunoglobulin G type (AGA IgG) — a higher rate than seen in healthy controls. We performed the first double-blind clinical trial of gluten-free versus gluten-containing diets in a subset of patients with schizophrenia who were positive for AGA IgG...https://doi.org/10.1503/jpn.180174
September 2018
Kelly DL, Li X, Kilday C, Feldman S, Clark S, Liu F, Buchanan RW, Tonelli LH. Increased circulating regulatory T cells in medicated people with schizophrenia. Psychiatry Res. 2018 Nov;269:517-523. doi: 10.1016/j.psychres.2018.09.006. Epub 2018 Sep 5. PMID: 30195746; PMCID: PMC6207456.
Immunological abnormalities are increasingly reported in people with schizophrenia, but no clear functional biomarkers associated with genetic correlates of the disease have been found. Regulatory T cells (Tregs) are key immunoregulatory cells involved in the control of inflammatory processes and their functions are directly related to the human leucocyte antigen (HLA) gene, which has been implicated in schizophrenia genetic studies. However, there is a lack of studies reporting Treg status in people with schizophrenia. In the current study, the proportion of circulating Tregs was examined using flow cytometry in 26 medicated participants with schizophrenia and 17 healthy controls...https://doi.org/10.1016/j.psychres.2018.09.006